Symbols

Symbols

NUVL

NUVL

Nuvalent shares surge 17.46% after-hours after announcing pivotal data for ALK inhibitor neladalkib in lung cancer trial.

Nuvalent to Discuss Pivotal Data for Neladalkib in Advanced ALK-positive NSCLC

Wednesday Nov 12, 2025

Nuvalent's 15min chart triggers MACD Death Cross and Bearish Marubozu formation.

Nuvalent: Canaccord Genuity Initiates Coverage on Buy with PT $126

Tuesday Nov 11, 2025

Nuvalent's 15-Min Chart Shows RSI Overbought, KDJ Death Cross.

Wednesday Nov 05, 2025

Nuvalent's 15min chart shows MACD Death Cross, Bearish Marubozu formation.

Tuesday Nov 04, 2025

Nuvalent to Present ARROS-1 Trial Data at 2025 IASLC ASCO North America Conference on Lung Cancer

Sunday Nov 02, 2025

Nuvalent Inc Reports Q3 2025 EPS Miss, Maintains Strong Cash Position for Future Growth

Friday Oct 31, 2025

Nuvalent: Barclays Raises PT to $112, Maintains Overweight Rating

Nuvalent, Inc. Announces Insider Transactions Amidst Market Volatility.

Nuvalent:UBS Boosts Nuvalent Buy Rating to $132, Raises PT

Thursday Oct 30, 2025

Nuvalent's 15min chart signals MACD, KDJ Death Crosses with caution.

Nuvalent Reports Wider Q3 Net Loss Amid Biopharma Struggles

Nuvalent Highlights Pipeline Progress, Reports Q3 2025 Financials, Operating Runway into 2028.

Nuvalent Completes NDA Submission for Zidesamtinib in Advanced ROS1-Positive NSCLC.

Wednesday Oct 29, 2025

Nuvalent Director Shair Matthew sells 4,046 shares at $100.23 on Oct 27.

Nuvalent's 15min chart signals MACD, KDJ Death Crosses with caution.

Nuvalent's Fair Value Estimated at $150, 33% Undervalued Based on 2 Stage Free Cash Flow to Equity Model

Tuesday Oct 28, 2025

Nuvalent's 15-min chart triggers MACD Death Cross, Bollinger Bands Narrowing.

Monday Oct 27, 2025

Nuvalent's 15min chart signals RSI overbought and KDJ death cross.